Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-25T19:24:02.137Z Has data issue: false hasContentIssue false
  • English
  • Français

Relevance of measurement of bêta-2-microglobulin in schizophrenia

Published online by Cambridge University Press:  27 August 2024

A. Aissa ,
A. B. C. Arij ,
S. Jedda ,
F. Askri ,
R. Jomli  and
H. Abaza
A. Aissa*
Affiliation:
1Psychiatry A, Razi Hospital, Manouba 2Psychiatry, Faculty of Medicine of Tunis
A. B. C. Arij
Affiliation:
3Human genetic lab, Salah Azaiez Institute, Tunis
S. Jedda
Affiliation:
1Psychiatry A, Razi Hospital, Manouba
F. Askri
Affiliation:
1Psychiatry A, Razi Hospital, Manouba
R. Jomli
Affiliation:
1Psychiatry A, Razi Hospital, Manouba
H. Abaza
Affiliation:
4Clinical biology, Razi Hospital, Manouba, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There are several arguments supporting the inflammatory hypothesis in schizophrenia (SCZ). Among the inflammatory markers, beta-2- microglobulin (β2M) is associated with abnormalities in neurogenesis and cognitive impairment described in (SCZ).

Objectives

The objectives of our study were to evaluate the level of β2M in a group of patients compared with a control group and to investigate the sociodemographic, clinical, and environmental factors associated with elevated β2M levels

Methods

We conducted a cross-sectional in outpatients with SCZ. We collected patients sociodemographic, environmental, and clinical data. We assessed psychopathology with the PANSS. We measured serum β2M concentration.

Results

We included 30 patients with SCZ compared with 20 controls. Patients mean age was 40,23±10,66. The mean level of β2M was 1,98 ± 0.42 mg/L for patients and 1.65±0.56 mg/L for control group. The difference was significant between the patient group and the control group (p<10-3). No environmental or clinical factors have been associated with β2M levels other than smoking status (p=0.046).

Conclusions

Further research with larger samples investigating the different stages of SCZ especially early psychosis would be needed to confirm the relevance of this biomarker in SCZ.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 67 , Special Issue S1: Abstracts of the 32nd European Congress of Psychiatry , April 2024 , pp. S125 - S126
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.